LRRK2
LRRK2 Molekülinformation
| Englischer Name | Leucine-rich repeat serine/threonine-protein kinase 2 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 11 | Target-Alias | PARK8，LRRK2，Leucine Rich Repeat Kinase 2，Leucine-Rich Repeat Serine/Threonine-Protein Kinase 2，Parkinson Disease (Autosomal Dominant) 8，Augmented In Rheumatoid Arthritis 17，Dardarin，AURA17，RIPK7，ROCO2，Leucine-Rich Repeat Serine-Threonine Protein Kinase-2，DKFZp434H2111，FLJ45829 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | Leucine-rich repeat serine/threonine-protein kinase 2 |
| Target-Alias | PARK8，LRRK2，Leucine Rich Repeat Kinase 2，Leucine-Rich Repeat Serine/Threonine-Protein Kinase 2，Parkinson Disease (Autosomal Dominant) 8，Augmented In Rheumatoid Arthritis 17，Dardarin，AURA17，RIPK7，ROCO2，Leucine-Rich Repeat Serine-Threonine Protein Kinase-2，DKFZp434H2111，FLJ45829 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 11 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
Produktanfrage
LRRK2 Molekülalias
PARK8,Leu-rich repeat,LRR-containing protein kinase 2,Dardarin
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| BIIB-094 | BIIB-094; ION-859; IONIS-BIIB7Rx | Phase 2 Clinical | Biogen Inc | Parkinson Disease | Details |
| NEU-411 | NEU-411 | Phase 2 Clinical | Neuron23 Inc | Parkinsonian Disorders; Parkinson Disease | Details |
| DNL-151 | BIIB122; DNL151; BIIB-122; DNL-151 | Phase 2 Clinical | Genentech Inc | Parkinson Disease | Details |
| VRN-01 | VRN-01 | Phase 1 Clinical | Voronoi Inc | Glioblastoma | Details |
| LRRK2 Kinase Inhibitors (Oncodesign/Servier) | ODS-2005294 | Phase 1 Clinical | Neoplasms; Parkinson Disease; Central Nervous System Diseases | Details | |
| OPM-201 | OPM-201; S-221237 | Phase 1 Clinical | Oncodesign Biotechnology | Parkinson Disease | Details |
| ARV-102 | ARV-102 | Phase 1 Clinical | Arvinas Inc | Supranuclear Palsy, Progressive; Parkinson Disease | Details |
| HT-4253 | HT-4253 | Phase 1 Clinical | Halia Therapeutics Inc | Alzheimer Disease | Details |
| FB418 | FB418 | Phase 1 Clinical | 1st Biotherapeutics Inc | Parkinsonian Disorders; Parkinson Disease; Amyotrophic Lateral Sclerosis | Details |
| WXWH0226 | WXWH0226; WXWH-0226 | Phase 1 Clinical | Guizhou Inochini Technology Co Ltd, Wuxi Apptec Co Ltd | Parkinson Disease | Details |
| BT-0267 | BT 267; BT-0267 | Clinical | Brenig Therapeutics Inc | Parkinson Disease | Details |
- Molekülinformation
- Produktanfrage
- Klinische Arzneimittelinformation